LEXICON PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.30 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-03-03
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.30, a 52.58% decline from fiscal 2021.
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $4.85, a 106.38% increase from fiscal 2020.
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $2.35, a 26.10% decline from fiscal 2019.
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $3.18, a 43.52% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2022-12-31 | $2.30 10-K · filed 2023-03-03 | |
| 2021-12-31 | $4.85 10-K · filed 2023-03-03 | |
| 2020-12-31 | $2.35 10-K · filed 2023-03-03 | |
| 2019-12-31 | $3.18 10-K · filed 2022-03-10 | |
| 2018-12-31 | $5.63 10-K · filed 2021-03-12 | |
| 2017-12-31 | $8.59 10-K · filed 2020-03-12 | |
| 2016-12-31 | $6.43 10-K · filed 2019-03-15 | |
| 2015-12-31 | $4.58 10-K · filed 2018-03-01 | |
| 2014-12-31 | $8.61 10-K · filed 2017-03-06 | $1.23 10-K · filed 2015-03-12 |
| 2013-12-31 | $11.13 10-K · filed 2016-03-11 | $1.59 10-K · filed 2014-03-07 |
| 2012-12-31 | $1.37 10-K · filed 2015-03-12 | |
| 2011-12-31 | $1.36 10-K · filed 2014-03-07 | |
| 2010-12-31 | $1.40 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |